Premium
P3‐368: PREDICTING AND MONITORING SHORT‐TERM DISEASE PROGRESSION IN A‐MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS
Author(s) -
Marizzoni Moira,
Ferrari Clarissa,
Cavaliere Libera,
Didic Mira,
Forloni Gianluigi,
Jovicich Jorge,
Molinuevo José Luis,
Nobili Flavio,
Parnetti Lucilla,
Payoux Pierre,
Ribaldi Federica,
Rossini Paolo Maria,
Schonknecht Peter,
Soricelli Andrea,
Tsolaki Magda,
Visser Pieter Jelle,
Wiltfang Jens,
Richardson Jill,
Bordet Régis,
Blin Olivier,
Frisoni Giovanni B.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1730
Subject(s) - biomarker , diffusion mri , medicine , imaging biomarker , cohort , sample size determination , oncology , magnetic resonance imaging , cerebrospinal fluid , nuclear medicine , radiology , biology , statistics , mathematics , biochemistry
the tests or the composite score (Ab+ -0.21 SD/year vs. Ab -0.17 SD/year, p1⁄40.50) (Table). Conclusions: In individuals aged 90 and older, high amyloid burden on florbetapir-PET was associated with worse cognitive performance at baseline but not with a faster rate of cognitive decline over an average of 1.7 years. Possible explanations for this discrepancy include a short follow-up, decline in people with Ab+ scans beginning at a younger age, or the frequent presence of non-AD pathologies at this age obscuring the relationship between amyloid and cognition.